Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFOCUS: Riluzole for Preventing Cognitive Dysfunction in Cancer Patients Receiving Chemotherapy
NCT07447050Phase 2Recruiting
- Sponsor
- University of California, Irvine
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cognitive dysfunction comparing Riluzole with Placebo (2 arms). Primary endpoint: Change in circulating Brain-Derived Neurotrophic Factor levels at 6 months. Started Dec 2025; status: recruiting.
02
Drugs
riluzole
03
Conditions
cognitive dysfunction
Beyond the preview
Go deeper on NCT07447050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07447050.